The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis
Open accessAbstract
Objective: We sought to determine whether vitamin D status is associated with developing new T2 lesions or contrast‐enhancing lesions on brain magnetic resonance imaging (MRI) in relapsing multiple sclerosis (MS). Methods: EPIC is a 5‐year longitudinal MS cohort study at the University of California at San Francisco. Participants had clinical evaluations, brain MRI, and blood draws annually. From the overall cohort, we evaluated patients with clinically isolated syndrome or relapsing–remitting MS at baseline. In univariate and multivariate (adjusted for age, sex, ethnicity, smoking, and MS treatments) repeated measures analyses, annual 25‐hydroxyvitamin D levels were evaluated for their association with subsequent new T2‐weighted and gadolinium‐enhancing T1‐weighted lesions on brain MRI, clinical relapses, and disability (Expanded Disability Status Scale [EDSS]). Results: A total of 2,362 3T brain MRI scans were acquired from 469 subjects. In multivariate analyses, each 10ng/ml higher 25‐hydroxyvitamin D level was associated with a 15% lower risk of a new T2 lesion (incidence rate ratio [IRR], 0.85; 95% confidence interval [CI], 0.76–0.95; p = 0.004) and a 32% lower risk of a gadolinium‐enhancing lesion (IRR, 0.68; 95% CI, 0.53–0.87; p = 0.002). Each 10ng/ml higher vitamin D level was associated with lower subsequent disability (−0.047; 95% CI, −0.091 to −0.003; p = 0.037). Higher vitamin D levels were associated with lower, but not statistically significant, relapse risk. Except for the EDSS model, all associations were stronger when the within‐person change in vitamin D level was the predictor. Interpretation: Vitamin D levels are inversely associated with MS activity on brain MRI. These results provide further support for a randomized trial of vitamin D supplementation. ANN NEUROL 2012;72:234–240.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis
Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006) · JAMA · doi:10.1001/jama.296.23.2832 · Cited by 1,897
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861
Ramagopalan, S. V., Maugeri, N. J., Handunnetthi, L., Lincoln, M. R., Orton, S.-M., Dyment, D. A., DeLuca, G. C., Herrera, B. M., Chao, M. J., Sadovnick, A. D., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000369 · Cited by 519
Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis
Simpson, S., Taylor, B., Blizzard, L., Ponsonby, A., Pittas, F., Tremlett, H., Dwyer, T., Gies, P., & van der Mei, I. (2010) · Annals of Neurology · doi:10.1002/ana.22043 · Cited by 457
Levin, L. I. (2005) · JAMA · doi:10.1001/jama.293.20.2496 · Cited by 448
Vitamin D status is associated with relapse rate in pediatric‐onset multiple sclerosis
Mowry, E. M., Krupp, L. B., Milazzo, M., Chabas, D., Strober, J. B., Belman, A. L., McDonald, J. C., Oksenberg, J. R., Bacchetti, P., & Waubant, E. (2010) · Annals of Neurology · doi:10.1002/ana.21972 · Cited by 329
Self-citationAssociation between clinical disease activity and Epstein–Barr virus reactivation in MS
Wandinger, K.-P., Jabs, W., Siekhaus, A., Bubel, S., Trillenberg, P., Wagner, H.-J., Wessel, K., Kirchner, H., & Hennig, H. (2000) · Neurology · doi:10.1212/wnl.55.2.178 · Cited by 302
Cited by
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression
Ascherio, A., Munger, K. L., White, R., Köchert, K., Simon, K. C., Polman, C. H., Freedman, M. S., Hartung, H.-P., Miller, D. H., Montalbán, X., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5993 · Cited by 516
Vitamin D and inflammatory diseases
Agrawal, D., & Yin, K. (2014) · Journal of Inflammation Research · doi:10.2147/jir.s63898 · Cited by 468
Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study
Mokry, L. E., Ross, S., Ahmad, O. S., Forgetta, V., Smith, G. D., Leong, A., Greenwood, C. M. T., Thanassoulis, G., & Richards, J. B. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001866 · Cited by 445
Long‐term evolution of multiple sclerosis disability in the treatment era
University of California, S. F. M. T., Cree, B. A. C., Gourraud, P., Oksenberg, J. R., Bevan, C., Crabtree‐Hartman, E., Gelfand, J. M., Goodin, D. S., Graves, J., Green, A. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24747 · Cited by 440
Self-citationVitamin D and Multiple Sclerosis: A Comprehensive Review
Sintzel, M. B., Rametta, M., & Reder, A. T. (2018) · Neurology and Therapy · doi:10.1007/s40120-017-0086-4 · Cited by 435
Environmental factors in multiple sclerosis
Ascherio, A. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.865866 · Cited by 330
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Rotstein, D., & Montalban, X. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0170-8 · Cited by 289
Vitamin D and multiple sclerosis: An update
Pierrot-Deseilligny, C., & Souberbielle, J.-C. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.03.014 · Cited by 265
Body fluid biomarkers in multiple sclerosis
Comabella, M., & Montalban, X. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70233-3 · Cited by 258
Camu, W., Tremblier, B., Plassot, C., Alphandery, S., Salsac, C., Pageot, N., Juntas-Morales, R., Scamps, F., Daures, J.-P., & Raoul, C. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.005 · Cited by 95
A systematic review of modifiable risk factors in the progression of multiple sclerosis
Hempel, S., Graham, G. D., Fu, N., Estrada, E., Chen, A. Y., Miake-Lye, I., Miles, J. N. V., Shanman, R., Shekelle, P. G., Beroes, J. M., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517690270 · Cited by 77
Bhargava, P., Cassard, S., Steele, S. U., Azevedo, C., Pelletier, D., Sugar, E. A., Waubant, E., & Mowry, E. M. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.10.004 · Cited by 69
Self-citationStress-Axis Regulation by Vitamin D3 in Multiple Sclerosis
Rolf, L., Damoiseaux, J., Huitinga, I., Kimenai, D., van den Ouweland, J., Hupperts, R., & Smolders, J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00263 · Cited by 28
Metadata
- Authors
- Mowry, E. M., Waubant, E., McCulloch, C. E., Okuda, D. T., Evangelista, A. A., Lincoln, R. R., Gourraud, P., Brenneman, D., Owen, M. C., Qualley, P., Bucci, M., Hauser, S. L., & Pelletier, D.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-08
- Volume
- 72
- Issue
- 2
- Pages
- 234-240
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2015961398
- Cited by
- 270
- References
- 28
- FWCI
- 18.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.